1. Home
  2. LLYVA vs CYTK Comparison

LLYVA vs CYTK Comparison

Compare LLYVA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Media Corporation Series A Liberty Live

LLYVA

Liberty Media Corporation Series A Liberty Live

HOLD

Current Price

$82.93

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.38

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LLYVA
CYTK
Founded
1991
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
8.0B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
LLYVA
CYTK
Price
$82.93
$63.38
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
$77.87
AVG Volume (30 Days)
198.8K
1.7M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$87,211,000.00
Revenue This Year
N/A
$361.33
Revenue Next Year
$10.22
$65.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2609.26
52 Week Low
$59.45
$29.31
52 Week High
$99.63
$69.33

Technical Indicators

Market Signals
Indicator
LLYVA
CYTK
Relative Strength Index (RSI) 57.62 50.08
Support Level $77.61 $59.56
Resistance Level $81.15 $67.26
Average True Range (ATR) 2.28 2.45
MACD 1.08 -0.77
Stochastic Oscillator 88.03 39.05

Price Performance

Historical Comparison
LLYVA
CYTK

About LLYVA Liberty Media Corporation Series A Liberty Live

Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: